Cargando…

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study

BACKGROUND: Letermovir (LTV) is effective for prevention (ppx) of primary clinically significant CMV infection (csCMVi) in the first 100 days after hematopoietic cell transplant (HCT). Data on LTV for secondary ppx is limited. We report on the efficacy and safety of LTV administered for 14 weeks as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Gyuri, Stern, Anat, Su, Yiqi, Gyurkocza, Boglarka, Sauter, Craig, Shaffer, Brian, Papanicolaou, Genovefa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644769/ http://dx.doi.org/10.1093/ofid/ofab466.793

Ejemplares similares

1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience
por: Zavras, Phaedon D, et al.
Publicado: (2019)

91. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT)
por: Stern, Anat, et al.
Publicado: (2019)

1761. A Single-Center Experience with Cidofovir for the Treatment of Double-Stranded (ds) DNA Viruses in Hematopoietic Cell Transplant (HCT) Recipients
por: Stern, Anat, et al.
Publicado: (2019)

1104. Risk Factors and Outcomes of Refractory and/or Resistant Cytomegalovirus (CMV) Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Karantoni, Eleni, et al.
Publicado: (2020)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Severe influenza and S. aureus pneumonia: For whom the bell tolls?
por: Papanicolaou, Genovefa A
Publicado: (2013)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

2735. Treatment patterns and clinical outcomes of acyclovir resistant and refractory human herpes simplex virus infection after allogeneic hematopoietic cell transplantation
por: Lee, Yeon Joo, et al.
Publicado: (2023)

1855. Understanding Cytomegalovirus (CMV) Symptom Management, Quality of Life, and Care Coordination in Transplant Recipients Through Patient and Care Partner (CP) Experiences
por: Singh, Deepshikha, et al.
Publicado: (2023)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection
por: Shah, Nishi, et al.
Publicado: (2022)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

2717. The Impact of Pneumococcal Conjugate Vaccine in Nonbacteremic Pneumococcal Pneumonia Among Cancer Patients
por: Lee, Yeon Joo, et al.
Publicado: (2019)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

BK Polyoma Virus Nephropathy in Hematopoietic Cell Transplant Recipients with Renal Dysfunction
por: Lee, Yeon Joo, et al.
Publicado: (2017)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study
por: Schulte, Johannes H, et al.
Publicado: (2023)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Frequently Asked Questions about Mpox (Formerly Monkeypox Disease) for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Recipients from the American Society for Transplantation and Cellular Therapy
por: Ford, Emily S., et al.
Publicado: (2023)

1563. Relationship of Cumulative Viral Burden of Adenovirus with Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Early Adenovirus Viremia
por: Lee, Yeon Joo, et al.
Publicado: (2018)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

Impacts and Challenges of Advanced Diagnostic Assays for Transplant Infectious Diseases
por: Babady, N. Esther, et al.
Publicado: (2018)

Acetobacter tropicalis bacteraemia in an immunocompromised patient: case report
por: Raible, Kevin M., et al.
Publicado: (2022)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
por: Kamboj, Mini, et al.
Publicado: (2008)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
por: Prockop, Susan E., et al.
Publicado: (2023)

452 Pseudo-Outbreak of Fulminant Toxoplasmosis in Hematopoietic Stem Cell Transplant [HSCT] Recipients
por: Isa, Flonza, et al.
Publicado: (2014)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4166i4qmgughfddq6vpqkdu3em